Blume J, Claus L, Isermann T, Dickmanns A, Conradi L, Schulz-Heddergott R
Cell Cycle. 2023; 22(13):1563-1582.
PMID: 37266562
PMC: 10361147.
DOI: 10.1080/15384101.2023.2217003.
Kanne J, Hussong M, Isensee J, Munoz-Lopez A, Wolffgramm J, Hess F
Cell Death Dis. 2021; 12(6):530.
PMID: 34031359
PMC: 8144429.
DOI: 10.1038/s41419-021-03810-9.
Kciuk M, Marciniak B, Kontek R
Int J Mol Sci. 2020; 21(14).
PMID: 32664667
PMC: 7404108.
DOI: 10.3390/ijms21144919.
Sinha B
J Cancer Sci Ther. 2019; 8:244-251.
PMID: 31844487
PMC: 6914264.
DOI: 10.4172/1948-5956.1000421.
Sinha B, van T Erve T, Kumar A, Bortner C, Motten A, Mason R
Free Radic Biol Med. 2017; 113:406-412.
PMID: 29079526
PMC: 5699936.
DOI: 10.1016/j.freeradbiomed.2017.10.377.
Nitric oxide inhibits ATPase activity and induces resistance to topoisomerase II-poisons in human MCF-7 breast tumor cells.
Sinha B, Kumar A, Mason R
Biochem Biophys Rep. 2017; 10:252-259.
PMID: 28955753
PMC: 5614683.
DOI: 10.1016/j.bbrep.2017.04.011.
Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.
Kumar A, Ehrenshaft M, Tokar E, Mason R, Sinha B
Biochim Biophys Acta. 2016; 1860(7):1519-27.
PMID: 27095671
PMC: 4909546.
DOI: 10.1016/j.bbagen.2016.04.009.
Nitric Oxide Down-Regulates Topoisomerase I and Induces Camptothecin Resistance in Human Breast MCF-7 Tumor Cells.
Sharma N, Kumar A, Kumari A, Tokar E, Waalkes M, Bortner C
PLoS One. 2015; 10(11):e0141897.
PMID: 26540186
PMC: 4635000.
DOI: 10.1371/journal.pone.0141897.
The role of BH3-mimetic drugs in the treatment of pediatric hepatoblastoma.
Lieber J, Armeanu-Ebinger S, Fuchs J
Int J Mol Sci. 2015; 16(2):4190-208.
PMID: 25690034
PMC: 4346952.
DOI: 10.3390/ijms16024190.
Expression of DNA topoisomerase II-α: Clinical significance in laryngeal carcinoma.
Feng Y, Zhang H, Gao W, Wen S, Huangfu H, Sun R
Oncol Lett. 2014; 8(4):1575-1580.
PMID: 25202370
PMC: 4156233.
DOI: 10.3892/ol.2014.2367.
Mechanisms regulating resistance to inhibitors of topoisomerase II.
Ganapathi R, Ganapathi M
Front Pharmacol. 2013; 4:89.
PMID: 23914174
PMC: 3729981.
DOI: 10.3389/fphar.2013.00089.
Selective enhancing effect of early mitotic inhibitor 1 (Emi1) depletion on the sensitivity of doxorubicin or X-ray treatment in human cancer cells.
Shimizu N, Nakajima N, Tsunematsu T, Ogawa I, Kawai H, Hirayama R
J Biol Chem. 2013; 288(24):17238-52.
PMID: 23645673
PMC: 3682528.
DOI: 10.1074/jbc.M112.446351.
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K.
Munck J, Batey M, Zhao Y, Jenkins H, Richardson C, Cano C
Mol Cancer Ther. 2012; 11(8):1789-98.
PMID: 22576130
PMC: 3428850.
DOI: 10.1158/1535-7163.MCT-11-0535.
Gene expression analysis for predicting gemcitabine sensitivity in pancreatic cancer patients.
Bai J, Sata N, Nagai H
HPB (Oxford). 2008; 9(2):150-5.
PMID: 18333132
PMC: 2020785.
DOI: 10.1080/13651820601175918.
Topoisomerase I amino acid substitutions, Gly185Arg and Asp325Glu, confer camptothecin resistance in Leishmania donovani.
Marquis J, Hardy I, Olivier M
Antimicrob Agents Chemother. 2005; 49(4):1441-6.
PMID: 15793124
PMC: 1068627.
DOI: 10.1128/AAC.49.4.1441-1446.2005.
Cytotoxicity of psammaplin A from a two-sponge association may correlate with the inhibition of DNA replication.
Jiang Y, Ahn E, Ryu S, Kim D, Park J, Yoon H
BMC Cancer. 2004; 4:70.
PMID: 15456519
PMC: 524492.
DOI: 10.1186/1471-2407-4-70.
ATM and the catalytic subunit of DNA-dependent protein kinase activate NF-kappaB through a common MEK/extracellular signal-regulated kinase/p90(rsk) signaling pathway in response to distinct forms of DNA damage.
Panta G, Kaur S, Cavin L, Cortes M, Mercurio F, Lothstein L
Mol Cell Biol. 2004; 24(5):1823-35.
PMID: 14966265
PMC: 350545.
DOI: 10.1128/MCB.24.5.1823-1835.2004.
First-line treatment strategies to improve survival in patients with advanced colorectal cancer.
Gill S, Goldberg R
Drugs. 2004; 64(1):27-44.
PMID: 14723557
DOI: 10.2165/00003495-200464010-00003.
Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy: a novel treatment strategy.
Litvak D, Bilchik A, Cabot M
J Gastrointest Surg. 2003; 7(1):140-148.
PMID: 12559195
DOI: 10.1016/S1091-255X(02)00126-9.
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.
Schellens J, Heinrich B, Lehnert M, Gore M, Kaye S, Dombernowsky P
Invest New Drugs. 2002; 20(1):83-93.
PMID: 12003197
DOI: 10.1023/a:1014454821885.
